Smoking Cessation Products Global Market Report 2025

The smoking cessation products market size has grown strongly in recent years. It will grow from $22.25 billion in 2024 to $24.13 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. This historical growth can be credited to heightened awareness regarding the health dangers of smoking, an increase in smoking-related respiratory conditions, extensive government and public health initiatives encouraging smoking cessation, wider adoption of nicotine replacement solutions, and increased spending on healthcare due to smoking-related diseases.

The smoking cessation products market size is expected to see strong growth in the next few years. It will grow to $32.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. This anticipated growth will be driven by a rising number of individuals trying to quit smoking, the aging population with historically high smoking rates, favorable regulatory frameworks supporting cessation programs, a surge in tobacco-related cancer cases, and the implementation of more rigorous tobacco control measures and taxation policies. Key trends in the forecast period include diversification of product offerings, continued use of nicotine replacement therapies, improved ease of access to cessation solutions, integration of behavioral therapies with pharmacological aids, and advancements in technology for nicotine delivery methods.

The increasing prevalence of smoking-related diseases is expected to drive the growth of the smoking cessation products market in the coming years. These diseases, which result directly or indirectly from tobacco use, impact various organs and systems within the body. The continued use of tobacco prolongs exposure to harmful chemicals, leading to long-term damage and an elevated risk of chronic conditions. As the incidence of these diseases rises, growing health awareness and medical diagnoses are encouraging more individuals to seek effective ways to quit smoking, thereby increasing demand for cessation products. For example, in January 2025, the American Cancer Society reported that the United States is projected to see approximately 226,650 new lung cancer cases in 2025, with 110,680 in males and 115,970 in females. Lung cancer-related deaths are expected to reach around 124,730, including 64,190 men and 60,540 women. This increasing burden of smoking-related illnesses underscores the growing market for smoking cessation products.

Companies operating in the smoking cessation products market are emphasizing the launch of de-addiction campaigns to raise awareness and foster community support that improves recovery outcomes and helps prevent relapse. These campaigns aim to support individuals struggling with substance dependence and promote healthier lifestyle choices. For instance, in April 2023, Rusan Pharma, an India-based pharmaceutical company, introduced a tobacco de-addiction campaign through its brand 2baconil, which offers a 24-hour nicotine transdermal patch. The campaign, titled #NoReasonIsGoodEnough, was built around the idea that individuals often justify their smoking habits with various reasons. It highlights how 2baconil’s nicotine patches can help reduce both the physical and psychological reliance on nicotine. The brand’s product offerings include both nicotine patches and gum to aid individuals in quitting smoking.

In April 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical firm, acquired the global Nicotine Replacement Therapy (NRT) business of Haleon Plc for $619 million. This acquisition brought into Dr. Reddy’s portfolio Nicotinell, a leading global brand in nicotine replacement therapy with a presence in more than 30 countries across Europe, Asia, and Latin America. It also included other notable regional brands such as Nicabate, Thrive, and Habitrol. The product range includes lozenges, patches, gums, and other upcoming products, serving major international markets, excluding the United States. Haleon Plc is a UK-based company that manufactures smoking cessation products.

Major players in the smoking cessation products market are Pfizer Inc., Johnson & Johnson, Novartis AG, Imperial Brands PLC, GlaxoSmithKline (GSK), British American Tobacco PLC, Philip Morris International Inc., Haleon Group of Companies, Perrigo Company, Dr. Reddy's Laboratories, Cipla Ltd., Fertin Pharma, Lucy, Euro-Pharm International Canada Inc., Alkalon A/S, Enorama Pharma AB, Niconovum AB, Sparsha Pharma International Pvt Ltd, The Harvard Drug Group, and Revolymer.

North America was the largest region in the smoking cessation products market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in smoking cessation products report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the smoking cessation products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Smoking cessation products are therapeutic solutions developed to support individuals in reducing or completely stopping their tobacco use by addressing both the physical and psychological dependencies associated with nicotine addiction. These aids operate by either progressively decreasing nicotine levels in the body or offering alternatives that help manage cravings and withdrawal symptoms.

The primary categories of smoking cessation products include nicotine replacement therapy (NRT), prescription medications, over-the-counter remedies, and electronic cigarettes. NRT is a clinically approved method that delivers controlled amounts of nicotine to ease withdrawal symptoms and support smoking cessation efforts. It comes in various forms such as patches, gums, lozenges, nasal sprays, and inhalers, and is available through pharmacies, online platforms, supermarkets, and medical professionals. These products cater to a wide range of users, including adults, adolescents, and expectant mothers.

The smoking cessation products market research report is one of a series of new reports that provides smoking cessation products market statistics, including smoking cessation products industry global market size, regional shares, competitors with a smoking cessation products market share, detailed smoking cessation products market segments, market trends and opportunities, and any further data you may need to thrive in the smoking cessation products industry. This smoking cessation products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The smoking cessation products market consists of sales of non-nicotine prescription medications, quit smoking supplements, and detox and recovery aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.